150330-40-8Relevant articles and documents
Benzazaborinines as novel bioisosteric replacements of naphthalene: Propranolol as an example
Rombouts, Frederik J. R.,Tovar, Fulgencio,Austin, Nigel,Tresadern, Gary,Trabanco, Andrés A.
, p. 9287 - 9295 (2015)
Two benzazaborinine analogues of propranolol were synthesized and extensively profiled in vitro and in vivo. These analogues showed potency and physicochemical and in vitro ADME-tox profiles comparable to propranolol. In addition, both benzazaborinine ana
Development of isomerization and cycloisomerization with use of a ruthenium hydride with N-heterocyclic carbene and its application to the synthesis of heterocycles
Arisawa, Mitsuhiro,Terada, Yukiyoshi,Takahashi, Kazuyuki,Nakagawa, Masako,Nishida, Atsushi
, p. 4255 - 4261 (2007/10/03)
A pure ruthenium hydride complex with N-heterocyclic carbene (NHC) ligand was efficiently generated from the reaction of a second-generation Grubbs ruthenium catalyst with vinyloxytrimethylsilane and unambiguously characterized. This ruthenium hydride complex showed high catalytic activity for the selective isomerization of terminal olefin and for the cycloisomerization of 1,6-dienes. These reactions of N-allyl-o-vinylaniline lead to novel synthetic methods for heterocycles such as indoles and 3-methylene-2,3-dihydroindoles, which are useful synthons for bioactive natural products. These procedures address an important issue in diversity-oriented synthesis.
TRICYCLIC HETEROCYCLIC COMPOUND
-
, (2008/06/13)
Tricyclic heterocyclyl compounds having a general formula (I): wherein: R1 and R2 each represents H, a lower alkyl or lower alkoxy group, a halogen atom or halogeno-lower alkyl; R3 represents H or a lower alkyl group; R4 represents a substituted phenyl or
Structure-activity relationship of a series of phenylureas linked to 4- phenylimidazole. Novel potent inhibitors of acyl-CoA:cholesterol O- acyltransferase with antiatherosclerotic activity. 2
Kimura,Watanabe,Matsui,Hayashi,Tanaka,Ohtsuka,Saeki,Kogushi,Kabayashi,Akasaka,Yamagishi,Saitou,Yamatsu
, p. 1641 - 1653 (2007/10/02)
In our continuing search to find systemically bioavailable ACAT (acyl- CoA:cholesterol O-acyl-transferase) inhibitors with more potent antiatherosclerotic effect than N-[2-(dimethylamino)-6-[3-(5-methyl-4- phenyl-1H-imidazol-1-yl)propoxy]phenyl]-N'-pentyl